The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms, Chemico-Biological Interactions, vol.184, issue.1-2, pp.16-20, 2010. ,
DOI : 10.1016/j.cbi.2009.10.009
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009. ,
DOI : 10.1182/blood-2009-03-209262
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies, Blood Cancer Journal, vol.6, issue.7, p.333, 2015. ,
DOI : 10.1073/pnas.1422050112
& South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England, Haematologica, vol.91, pp.1400-1404, 2006. ,
Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain, Haematologica, vol.98, issue.8, pp.95-97, 2013. ,
DOI : 10.3324/haematol.2013.084061
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French - American - British Cooperative Leukaemia Group, British Journal of Haematology, vol.71, issue.4, pp.746-754, 1994. ,
DOI : 10.1016/0145-2126(79)90007-9
Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice, Current Hematologic Malignancy Reports, vol.52, issue.19, pp.301-310, 2014. ,
DOI : 10.1007/s11899-014-0225-2
World Health Organization classification of the acute leukemias and myelodysplastic syndrome, Int. J. Hematol, vol.72, pp.131-133, 2000. ,
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management, American Journal of Hematology, vol.90, issue.11, pp.967-974, 2013. ,
DOI : 10.1002/ajh.23574
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia, Blood, vol.125, issue.23, pp.3618-3626, 2015. ,
DOI : 10.1182/blood-2015-01-620781
Nomenclature of monocytes and dendritic cells in blood, Blood, vol.116, issue.16, pp.74-80, 2010. ,
DOI : 10.1182/blood-2010-02-258558
URL : https://hal.archives-ouvertes.fr/hal-00611173
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study, American Journal of Hematology, vol.31, issue.12, pp.1111-1115, 2014. ,
DOI : 10.1038/leu.2014.125
Cytogenetic risk stratification in chronic myelomonocytic leukemia, Haematologica, vol.96, issue.3, pp.375-383, 2011. ,
DOI : 10.3324/haematol.2010.030957
Clonal architecture of chronic myelomonocytic leukemias, Blood, vol.121, issue.12, pp.2186-2198, 2013. ,
DOI : 10.1182/blood-2012-06-440347
URL : https://hal.archives-ouvertes.fr/hal-00923316
An evolutionary perspective on chronic myelomonocytic leukemia, Leukemia, vol.120, issue.7, pp.1441-1450, 2013. ,
DOI : 10.1038/nature09367
Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations, Cellular and Molecular Life Sciences, vol.88, issue.Suppl 3, pp.2853-2861, 2012. ,
DOI : 10.1007/s00018-012-0956-y
Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-69, 2011. ,
DOI : 10.1038/nature10496
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia, Journal of Clinical Oncology, vol.31, issue.19, pp.2428-2436, 2013. ,
DOI : 10.1200/JCO.2012.47.3314
TIF1?: a tumor suppressor gene in chronic myelomonocytic leukemia, Med Sci, vol.27, pp.696-698, 2011. ,
Transcription intermediary factor 1?? is a tumor suppressor in mouse and human chronic myelomonocytic leukemia, Journal of Clinical Investigation, vol.121, issue.6, pp.2361-2370, 2011. ,
DOI : 10.1172/JCI45213DS1
The clinical management of chronic myelomonocytic leukemia, Clin Adv Hematol Oncol, vol.12, pp.172-178, 2014. ,
Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?, Best Practice & Research Clinical Haematology, vol.26, issue.4, pp.387-400, 2013. ,
DOI : 10.1016/j.beha.2013.09.006
International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-2088, 1997. ,
Revised International Prognostic Scoring System for Myelodysplastic Syndromes, Blood, vol.120, issue.12, pp.2454-2465, 2012. ,
DOI : 10.1182/blood-2012-03-420489
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes, Leukemia, vol.7, issue.7, pp.1504-1510, 2013. ,
DOI : 10.1186/1756-8722-5-12
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia, Blood, vol.121, issue.15, pp.3005-3015, 2013. ,
DOI : 10.1182/blood-2012-08-452938
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients, Leukemia, vol.28, issue.11, pp.2206-2212, 2014. ,
DOI : 10.1038/leu.2013.286
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group, Blood, vol.88, pp.2480-2487, 1996. ,
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial, Blood, vol.118, issue.14, pp.3824-3831, 2011. ,
DOI : 10.1182/blood-2011-05-352039
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia, Journal of Clinical Investigation, vol.125, issue.5, pp.1857-1872, 2015. ,
DOI : 10.1172/JCI78752DS1
5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal, Molecular and Cellular Biology, vol.25, issue.11 ,
DOI : 10.1128/MCB.25.11.4727-4741.2005
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme, Nucleic Acids Research, vol.38, issue.13, pp.4313-4324, 2010. ,
DOI : 10.1093/nar/gkq187
DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes, Seminars in Hematology, vol.45, issue.1, pp.23-30, 2008. ,
DOI : 10.1053/j.seminhematol.2007.11.007
Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents, Blood, vol.89, pp.2328-2335, 1997. ,
Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression, The Journal of Cell Biology, vol.127, issue.4, pp.1121-1127, 1994. ,
DOI : 10.1083/jcb.127.4.1121
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups, Haematologica, vol.98, issue.9, pp.1344-1352, 2013. ,
DOI : 10.3324/haematol.2013.084020
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities, Biology of Blood and Marrow Transplantation, vol.17, issue.6, pp.908-915, 2011. ,
DOI : 10.1016/j.bbmt.2010.09.018
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire, European Journal of Haematology, vol.151, issue.5, pp.355-364, 2013. ,
DOI : 10.1111/ejh.12073
Current status of allogeneic HST for chronic myelomonocytic leukemia, Bone Marrow Transplantation, vol.112, issue.4, pp.535-541, 2012. ,
DOI : 10.1038/bmt.2011.141
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia, Leukemia, vol.7, issue.9, pp.1707-1711, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1532
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes, Clinical Cancer Research, vol.15, issue.15, pp.5002-5007, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0494
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm, Journal of Clinical Investigation, vol.124, issue.6, pp.2762-2773, 2014. ,
DOI : 10.1172/JCI74182DS1
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038579
Signal transduction inhibitors in treatment of myelodysplastic syndromes, Journal of Hematology & Oncology, vol.6, issue.1, p.50, 2013. ,
DOI : 10.1080/10428190410001723322
Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates, Cancer Cell, vol.14, issue.4, pp.335-343, 2008. ,
DOI : 10.1016/j.ccr.2008.08.014
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults, Blood, vol.125, issue.12, pp.1857-1865, 2015. ,
DOI : 10.1182/blood-2014-10-607341
CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells, Cancer Research, vol.66, issue.13, pp.6807-6815, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-3755
<em>Ex vivo</em> generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer, Oncotarget, vol.6, issue.14, pp.12369-12382, 2015. ,
DOI : 10.18632/oncotarget.3682
Immature myeloid cells and cancer-associated immune suppression, Cancer Immunology, Immunotherapy, vol.51, issue.6, pp.293-298, 2002. ,
DOI : 10.1007/s00262-002-0280-8
Myeloid-derived suppressor cells as regulators of the immune system, Nature Reviews Immunology, vol.172, issue.3, pp.162-174, 2009. ,
DOI : 10.1038/nri2506
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity, Gut, vol.6, issue.11, pp.1769-1781, 2014. ,
DOI : 10.1136/gutjnl-2013-306271
Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma, Immunology, vol.123, issue.1, pp.141-149, 2009. ,
DOI : 10.1111/j.1365-2567.2009.03105.x
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion, Cancer Res, vol.65, pp.3044-3048, 2005. ,
Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes, Cancer Research, vol.69, issue.4, pp.1553-1560, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-1921
Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway, Gastroenterology, vol.135, issue.3, pp.871-881, 2008. ,
DOI : 10.1053/j.gastro.2008.06.032
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia, PLoS ONE, vol.90, issue.4, p.55818, 2013. ,
DOI : 10.1371/journal.pone.0055818.s007
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells, Oncotarget, vol.6, issue.12, pp.10532-10547, 2015. ,
DOI : 10.18632/oncotarget.3300
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans, Blood, vol.121, issue.15, pp.2975-2987, 2013. ,
DOI : 10.1182/blood-2012-08-448548
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics, Journal of Leukocyte Biology, vol.83, issue.5, pp.1136-1144, 2008. ,
DOI : 10.1189/jlb.0907611
The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins?, Seminars in Cancer Biology, vol.23, issue.3 ,
DOI : 10.1016/j.semcancer.2013.02.007
Coordinated regulation of myeloid cells by tumours, Nature Reviews Immunology, vol.205, issue.4, pp.253-268, 2012. ,
DOI : 10.1038/nri3175
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity, Blood, vol.111, issue.8, pp.4233-4244, 2008. ,
DOI : 10.1182/blood-2007-07-099226
Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer, The Journal of Immunology, vol.172, issue.1, pp.464-474, 2004. ,
DOI : 10.4049/jimmunol.172.1.464
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives, Immunological Reviews, vol.63, issue.3, pp.180-191, 2008. ,
DOI : 10.1084/jem.20061104
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia, Blood, vol.115, issue.1, pp.78-88, 2010. ,
DOI : 10.1182/blood-2009-05-224352
The roles of Dok family adapters in immunoreceptor signaling, Immunological Reviews, vol.191, issue.1, pp.273-285, 2009. ,
DOI : 10.1111/j.1600-065X.2009.00844.x
Dok-3, a Novel Adapter Molecule Involved in the Negative Regulation of Immunoreceptor Signaling, Molecular and Cellular Biology, vol.20, issue.8, pp.2743-2754, 2000. ,
DOI : 10.1128/MCB.20.8.2743-2754.2000
Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation, The Journal of Cell Biology, vol.14, issue.2, pp.345-354, 2001. ,
DOI : 10.1083/jcb.200102032
Dok-6, a Novel p62 Dok Family Member, Promotes Ret-mediated Neurite Outgrowth, Journal of Biological Chemistry, vol.279, issue.40 ,
DOI : 10.1074/jbc.M403726200
The Muscle Protein Dok-7 Is Essential for Neuromuscular Synaptogenesis, Science, vol.312, issue.5781, pp.1802-1805, 2006. ,
DOI : 10.1126/science.1127142
Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling, Genes Dev, vol.14, pp.11-16, 2000. ,
Role of Dok-1 and Dok-2 in Leukemia Suppression, The Journal of Experimental Medicine, vol.95, issue.12, pp.1689-1695, 2004. ,
DOI : 10.1038/sj.onc.1201005
Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia, The Journal of Experimental Medicine, vol.95, issue.12, pp.1681-1687, 2004. ,
DOI : 10.1038/sj.onc.1206620
Dok-1 and Dok-2 are negative regulators of T cell receptor signaling, International Immunology, vol.19, issue.4, pp.487-495, 2007. ,
DOI : 10.1093/intimm/dxm015
Identification of DOK genes as lung tumor suppressors, Nature Genetics, vol.121, issue.3, pp.216-223, 2010. ,
DOI : 10.1038/ng.527
Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma, Laboratory Investigation, vol.61, issue.9, pp.1357-1364, 2010. ,
DOI : 10.1016/j.ccr.2006.03.028
DOK2 as a Marker of Poor Prognosis of Patients with Gastric Adenocarcinoma After Curative Resection, Annals of Surgical Oncology, vol.49, issue.5, pp.1560-1567, 2012. ,
DOI : 10.1245/s10434-011-2157-6
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is??a Recurrent Event during Human Lymphomagenesis, Cancer Cell, vol.20, issue.1, pp.25-38, 2011. ,
DOI : 10.1016/j.ccr.2011.06.003
Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers, International Journal of Cancer, vol.32, issue.11, pp.2484-2494, 2012. ,
DOI : 10.1002/ijc.26299
URL : https://hal.archives-ouvertes.fr/hal-01262953
Dok1 expression and mutation in Burkitt's lymphoma cell lines, Cancer Letters, vol.245, issue.1-2, pp.44-50, 2007. ,
DOI : 10.1016/j.canlet.2005.10.045
Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia, Oncogene, vol.23, issue.13, pp.2287-2297, 2004. ,
DOI : 10.1038/sj.onc.1207385
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia, American Journal of Hematology, vol.116, issue.6, pp.604-609, 2014. ,
DOI : 10.1002/ajh.23702
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias, Leukemia Research, vol.38, issue.12, pp.1413-1419, 2014. ,
DOI : 10.1016/j.leukres.2014.09.003
Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder, PLoS ONE, vol.21, issue.12, p.28350, 2011. ,
DOI : 10.1371/journal.pone.0028350.s003
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy, Cell Cycle, vol.8, issue.9, pp.1781-1791, 2010. ,
DOI : 10.4161/cc.9.9.11483
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs, Cell Cycle, vol.8, issue.8, pp.1629-1638, 2010. ,
DOI : 10.4161/cc.9.8.11487
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant, Clinical Cancer Research, vol.16, issue.8, pp.2246-2256, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-2112
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin???cyclophosphamide chemotherapy, Cancer Immunology, Immunotherapy, vol.65, issue.1, pp.49-59, 2009. ,
DOI : 10.1007/s00262-008-0523-4
Circulating CD14+HLA-DR???/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC, Tumor Biology, vol.366, issue.8, pp.10-1007, 2015. ,
DOI : 10.1007/s13277-015-3426-y
Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunology, Immunotherapy, vol.119, issue.24, pp.1439-1451, 2013. ,
DOI : 10.1007/s00262-013-1450-6
BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity, Cancer Research, vol.74, issue.18, pp.5091-5102, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-3171
CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia, Oncol Lett, vol.9, pp.1167-1172, 2015. ,
New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients, British Journal of Haematology, vol.113, issue.3, pp.347-356, 2012. ,
DOI : 10.1111/j.1365-2141.2012.09069.x
URL : https://hal.archives-ouvertes.fr/inserm-00681007
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia, Blood, vol.124, issue.9, pp.1513-1521, 2014. ,
DOI : 10.1182/blood-2014-03-560227
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation, Blood, vol.114, issue.16, pp.3448-3458, 2009. ,
DOI : 10.1182/blood-2009-01-200519
The history of cancer epigenetics, Nature Reviews Cancer, vol.74, issue.2, pp.143-153, 2004. ,
DOI : 10.1038/nrc1279
The fundamental role of epigenetic events in cancer, Nat. Rev. Genet, vol.3, pp.415-428, 2002. ,
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia, Blood, vol.121, issue.25, pp.5068-5077, 2013. ,
DOI : 10.1182/blood-2012-10-460170
Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells, The Journal of Immunology, vol.185, issue.4, pp.2273-2284, 2010. ,
DOI : 10.4049/jimmunol.1000901
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer, Cancer Immunology, Immunotherapy, vol.21, issue.Suppl 2, pp.513-528, 2014. ,
DOI : 10.1007/s00262-014-1527-x